Communicators
are winners!
News
21.07.2009
Salugen (SYMBOL: SQZ.F) Announces Acquisition of CraniYums and Projects Record Revenues
Salugen (SYMBOL: SQZ.F) Announces Acquisition of CraniYums and Projects Record Revenues
Brain nutrigenomics leader acquires assets of Crania Co., LLC, the maker of CraniYums, to deliver clinically-proven ingredients in novel functional candy product line
ZURICH, SWITZERLAND and SAN DIEGO, CA USA – July 21, 2009 – Salugen® (SYMBOL: SQZ.F), a publicly-traded international life sciences company, announces today the acquisition of Crania Co., LLC, the maker of CraniYums (www.craniyums.com).
CraniYums is a proven technology platform which delivers clinically-supported all-natural ingredients to boost serotonin and dopamine levels in the brain.* In placebo-controlled clinical studies, patients taking CraniYums experienced significant improvements in mood and stress, as well as significant reductions in cravings.* Salugen will incorporate its proprietary technology into the CraniYum delivery platform to introduce functional candy products into the market in the Fall of 2009.
“We are very pleased to add the CraniYums technology platform to our offering,” states CEO Brian Meshkin. “By using the CraniYums functional candy as a delivery mechanism for our proprietary technology, we believe that we will revolutionize the world of sweets with clinical data supporting an all-natural, sugar-free, kosher certified functional candy product containing all-natural active ingredients.”
Over the past couple years CraniYums has been marketed by its inventor, Cheryl Hart, M.D. Dr. Hart is a Mayo Clinic trained physician from Spokane, Washington who has offered CraniYums to her patients and local community. The product has generated over $100,000 in annual sales through this one medical practice. Salugen believes that the market potential for this clinically-proven functional candy product line will exceed $500 million annually. Salugen projects record-setting revenues for 2009 due to this acquisition and the launch of its Salugen System into physicians’ offices.
Ron Grossman, President of Crania Co., LLC explains, “We are very excited to be joining Salugen and realizing the potential of the CraniYums technology platform. With the years of research and development spent putting together this proprietary technology, the product line is now ready for full-scale commercialization.”
To buy CraniYums today, please visit www.craniyums.com.
About Salugen AG
Salugen™ is a life sciences company offering nutritional ingredients and gene testing to help reduce excessive cravings involved in smoking, weight problems, and alcohol and drug abuse. Salugen has a patent-protected, clinically proven nutritional formulation to reduce stress and cravings, as well as patent-protected gene tests to help identify these persons and customize their treatment. Simply, Salugen’s goal is to reduce or eliminate the illness, costs, and deaths associated with these preventable disorders. For additional information about the company, please visit http://www.salugen.com.
Investor Relations Information Contact:
Petjo Noack, MA and Louis Philippe Antunes
Sherbrooke Equity Inc.
Seefeldstrasse 45
8032 Zürich
Tel.: 41 (0) 43 443 70 70
Fax.: 41 (0) 43 443 70 77
Web: www.sherbrookequity.com
Email: info@sherbrookeequity.com
Company Information Contact: Salugen AG, 877-258-4360, info@salugen.com, http://www.salugen.com .
* These statements have not been evaluated by the U.S. Food and Drug Administration. This product is not intended to diagnose, treat, cure or prevent any disease
Forward Looking Statements
Certain statements in this press release are forward-looking. These forward-looking statements include references to the use of our laboratory tests and nutritional products. These forward-looking statements are subject to risks and uncertainties and other factors, which may cause actual results to differ materially from the anticipated results or other expectations expressed in such forward-looking statements. These risks and uncertainties include, but are not limited to: the risk that physicians may not use the testing or products correctly; risks and uncertainties relating to the performance of our products; the growth in revenues; the size, timing and success or failure of any clinical trials; whether larger confirmatory clinical studies will confirm the results of initial studies; our ability to establish reliable, high-volume operations at commercially reasonable costs; expected reliance on physicians selling our products for a majority of our revenues; the annual renewal of certain customer agreements; actual market acceptance of our products and adoption of our technological approach and products; our estimate of the size of our markets; our estimates of the levels of demand for our products; the impact of competition; whether payers will authorize reimbursement for our products and services and the amount of such reimbursement that may be allowed; whether the FDA or any other agency will decide to further regulate our products or services; whether actions by the FDA, FTC or any other state regulatory body will restrict our ability to commercialize our products; whether we will encounter problems or delays in automating our processes; the ultimate validity and enforceability of our patent applications and patents; the possible infringement of the intellectual property of others; whether licenses to third party technology will be available; whether we are able to build brand loyalty and expand revenues; and whether we will be able to raise sufficient capital in the future, if required. We do not undertake, and specifically disclaim any obligation, to revise any forward-looking statements to reflect the occurrence of anticipated or unanticipated events or circumstances after the date of such statements.
NEWSLETTER REGISTRIERUNG:
Aktuelle Pressemeldungen dieses Unternehmens direkt in Ihr Postfach:
http://www.irw-press.com/alert_subscription.php?lang=en&isin=CH0027529517
Mitteilung übermittelt durch IRW-Press.com. Für den Inhalt ist der Aussender
verantwortlich.
Kostenloser Abdruck mit Quellenangabe erlaubt.
Brain nutrigenomics leader acquires assets of Crania Co., LLC, the maker of CraniYums, to deliver clinically-proven ingredients in novel functional candy product line
ZURICH, SWITZERLAND and SAN DIEGO, CA USA – July 21, 2009 – Salugen® (SYMBOL: SQZ.F), a publicly-traded international life sciences company, announces today the acquisition of Crania Co., LLC, the maker of CraniYums (www.craniyums.com).
CraniYums is a proven technology platform which delivers clinically-supported all-natural ingredients to boost serotonin and dopamine levels in the brain.* In placebo-controlled clinical studies, patients taking CraniYums experienced significant improvements in mood and stress, as well as significant reductions in cravings.* Salugen will incorporate its proprietary technology into the CraniYum delivery platform to introduce functional candy products into the market in the Fall of 2009.
“We are very pleased to add the CraniYums technology platform to our offering,” states CEO Brian Meshkin. “By using the CraniYums functional candy as a delivery mechanism for our proprietary technology, we believe that we will revolutionize the world of sweets with clinical data supporting an all-natural, sugar-free, kosher certified functional candy product containing all-natural active ingredients.”
Over the past couple years CraniYums has been marketed by its inventor, Cheryl Hart, M.D. Dr. Hart is a Mayo Clinic trained physician from Spokane, Washington who has offered CraniYums to her patients and local community. The product has generated over $100,000 in annual sales through this one medical practice. Salugen believes that the market potential for this clinically-proven functional candy product line will exceed $500 million annually. Salugen projects record-setting revenues for 2009 due to this acquisition and the launch of its Salugen System into physicians’ offices.
Ron Grossman, President of Crania Co., LLC explains, “We are very excited to be joining Salugen and realizing the potential of the CraniYums technology platform. With the years of research and development spent putting together this proprietary technology, the product line is now ready for full-scale commercialization.”
To buy CraniYums today, please visit www.craniyums.com.
About Salugen AG
Salugen™ is a life sciences company offering nutritional ingredients and gene testing to help reduce excessive cravings involved in smoking, weight problems, and alcohol and drug abuse. Salugen has a patent-protected, clinically proven nutritional formulation to reduce stress and cravings, as well as patent-protected gene tests to help identify these persons and customize their treatment. Simply, Salugen’s goal is to reduce or eliminate the illness, costs, and deaths associated with these preventable disorders. For additional information about the company, please visit http://www.salugen.com.
Investor Relations Information Contact:
Petjo Noack, MA and Louis Philippe Antunes
Sherbrooke Equity Inc.
Seefeldstrasse 45
8032 Zürich
Tel.: 41 (0) 43 443 70 70
Fax.: 41 (0) 43 443 70 77
Web: www.sherbrookequity.com
Email: info@sherbrookeequity.com
Company Information Contact: Salugen AG, 877-258-4360, info@salugen.com, http://www.salugen.com .
* These statements have not been evaluated by the U.S. Food and Drug Administration. This product is not intended to diagnose, treat, cure or prevent any disease
Forward Looking Statements
Certain statements in this press release are forward-looking. These forward-looking statements include references to the use of our laboratory tests and nutritional products. These forward-looking statements are subject to risks and uncertainties and other factors, which may cause actual results to differ materially from the anticipated results or other expectations expressed in such forward-looking statements. These risks and uncertainties include, but are not limited to: the risk that physicians may not use the testing or products correctly; risks and uncertainties relating to the performance of our products; the growth in revenues; the size, timing and success or failure of any clinical trials; whether larger confirmatory clinical studies will confirm the results of initial studies; our ability to establish reliable, high-volume operations at commercially reasonable costs; expected reliance on physicians selling our products for a majority of our revenues; the annual renewal of certain customer agreements; actual market acceptance of our products and adoption of our technological approach and products; our estimate of the size of our markets; our estimates of the levels of demand for our products; the impact of competition; whether payers will authorize reimbursement for our products and services and the amount of such reimbursement that may be allowed; whether the FDA or any other agency will decide to further regulate our products or services; whether actions by the FDA, FTC or any other state regulatory body will restrict our ability to commercialize our products; whether we will encounter problems or delays in automating our processes; the ultimate validity and enforceability of our patent applications and patents; the possible infringement of the intellectual property of others; whether licenses to third party technology will be available; whether we are able to build brand loyalty and expand revenues; and whether we will be able to raise sufficient capital in the future, if required. We do not undertake, and specifically disclaim any obligation, to revise any forward-looking statements to reflect the occurrence of anticipated or unanticipated events or circumstances after the date of such statements.
NEWSLETTER REGISTRIERUNG:
Aktuelle Pressemeldungen dieses Unternehmens direkt in Ihr Postfach:
http://www.irw-press.com/alert_subscription.php?lang=en&isin=CH0027529517
Mitteilung übermittelt durch IRW-Press.com. Für den Inhalt ist der Aussender
verantwortlich.
Kostenloser Abdruck mit Quellenangabe erlaubt.